When Congress approved a bill that gives more oversight power to the FDA, one area of the debate escaped largely unscathed. Regulation of drug ads and the marketing tactics used by the pharmaceutical companies will not be tightened as a result of the legislation. In earlier drafts of the legislation, closer scrutiny of drug ads and the manner in which drugs are marketed was part of the bills. However, the drug companies got a powerful assist in the lobbying efforts from Madison Avenue. The country’s large marketing firms lobbied Congress and were successful in convincing legislators to drop strict controls on pharmaceutical advertising and marketing.